Showing 251-260 of 264 results for "".
- ASAPS 2018 Stats: Injectables, Other Non-Surgical Cosmetic Procedures Still Gaining Steamhttps://modernaesthetics.com/news/asaps-2018-stats-injectables-other-non-surgical-cosmetic-procedures-still-gaining-steam/2471936/Non-surgical cosmetic procedures are on the rise, according to 2018 statistics from The American Society for Aesthetic Plastic Surgery (ASAPS). The top 5 nonsurgical procedures performed by plastic surgeons in 2018 were: Botulinum Toxin 1,801,033 proce
- Vic A Narurkar, MD: Remembering a Legendhttps://modernaesthetics.com/news/vic-a-narurkar-md-remembering-a-legend/2471955/The dermatology community lost a true rock star with the sudden passing of Vic A Narurkar MD, FAAD in late January. Loved by so many, Dr. Narurkar was the Founder of the Bay Area Laser Institute in San Francisco and a past president of the American Society of Cosmetic Derma
- New from Lumenis: SPLENDOR X Laser Hair Removal Solutionhttps://modernaesthetics.com/news/new-from-lumenis-splendor-x-laser-hair-removal-solution/2472011/Lumenis Ltd. has launched SPLENDOR X, the first solid state laser system equipped with the unique BLEND X technology for fast and effective hair removal and skin solutions. The technology was showcased for the first time at the 2018 American Society of Dermatological Surgery (ASDS) in Phoenix thi
- Recros Medica Unveils the Nuvellus Brand for Its Novel Rotational Fractional Resection Technologyhttps://modernaesthetics.com/news/recros-medica-unveils-the-nuvellus-brand-for-its-novel-rotational-fractional-resection-technology/2472023/Recros Medica, Inc. is unveiling the Nuvellus brand at this week’s American Society of Plastic Surgery meeting. The company will display at booth #1264, where it will introduce Nuvellus as an innovative, minimally-invasive surgical procedure in develop
- ASDS 2018 Survey: Close to 70 percent of Consumers Thinking About Cosmetic Treatmentshttps://modernaesthetics.com/news/asds-2018-survey-close-to-70-percent-of-consumers-are-thinking-about-cosmetic-treatments/2472034/Almost 70 percent of consumers are considering a cosmetic treatment, and more than half would prefer to pay more up front to lower their annual skin care costs, according to the 2018 American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmeti
- Cutera Marks 20 Years of Innovationhttps://modernaesthetics.com/news/cuter-marks-20-years-of-innovation/2472102/Cutera, Inc. is celebrating 20 years of best-in-class product innovation with continued commitment to the industry and its providers, marking the milestone at the Annual Meeting of the American Society for Laser Medicine and Surgery in Dallas. In conjunction with the 20th&nbs
- New AAFPRS Data: More Than 30 Percent of Men Are Considering Nips and Tuckshttps://modernaesthetics.com/news/new-aafprs-data-more-than-30-percent-of-men-are-considering-nips-and-tucks/2472223/The plastic surgery ‘menaissaince’ may really be a thing, finds a new survey from the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS). It turns out that 31 percent of men said they are “extremely likely&rdq
- Nearly 10.5 Million Treatments Performed by ASDS Members in 2016https://modernaesthetics.com/news/nearly-105-million-treatments-performed-by-asds-members-in-2016/2472226/Dermatologic surgeons performed nearly 10.5 million medically necessary and cosmetic procedures in 2016 – five percent more than 2015 and up 31 percent since 2012, according to the 2016 American Society for Dermatologic Surgery (ASDS) Survey on D
- ASPS 2016 Stats: Cosmetic Surgery On The Risehttps://modernaesthetics.com/news/asps-2016-stats-cosmetic-surgery-on-the-rise/2472267/Fat is still phat – at least in some places like the breasts, butt and face, according to the annual statistics from the American Society of Plastic Surgeons (ASPS). Specifically, minimally invasive cosmetic fat injections incre
- Update: Revance Starts Phase III Studies on RT002 for Frown Lineshttps://modernaesthetics.com/news/revance-starts-phase-iii-studies-on-rt002-for-frown-lines/2472297/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials